Daniel Levy, M.D.
Daniel Levy, M.D., is director of the Center for Population Studies and director of the Framingham Heart Study, both with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).
As director of the Center for Population Studies, Dr. Levy is spearheading a new systems medicine research program known as the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease) that seeks to identify new biomarkers and pathways involved in cardiovascular disease through gene expression profiling and discovery proteomics and metabolomics. These research resources will be united with Framingham’s comprehensive genetic and phenotypic databases and will be made freely accessible to the public.
In addition to his research and administrative responsibilities, Dr. Levy currently serves on the Adult Treatment Panel (ATP IV), which is formulating national cholesterol guidelines. He also serves on the team that is developing new cardiovascular disease risk assessment tools to be used in determining risk factor treatment decisions.
Dr. Levy received a Bachelor of Arts degree from the University of Pennsylvania, Philadelphia, in 1976 and a Doctor of Medicine degree from Boston University School of Medicine in 1980. He completed a residency in internal medicine at University Hospital, Boston and a research fellowship in cardiology at Brigham and Women’s Hospital, and Harvard School of Public Health in 1985. That same year he joined the National Heart, Lung, and Blood Institute and the Framingham Heart Study and he became the study’s fourth director in 1994. In 2005, he returned to the classroom as a fellow in medical ethics at Harvard Medical School. Dr. Levy has a faculty appointment at Boston University School of Medicine, where he is professor of medicine and he holds an adjunct appointment at Harvard Medical School.
Dr. Levy has received many awards and twice received the National Institutes of Health Director’s Award for his research accomplishments. In November 2009, he was the recipient of the American Heart Association’s highest recognition for research achievements in epidemiology, the Population Research Prize.
Dr. Levy has mentored scores of research fellows and has published over 400 articles in leading medical journals. He authored a book about the revolution in understanding of heart disease titled “A Change of Heart” (published by Alfred A. Knopf), and is editor-in-chief of the journal Current Cardiovascular Risk Reports. Dr. Levy is a fellow of the American College of Cardiology and of the American Heart Association.
Dr. Levy In the News
An international team of researchers has identified 11 new DNA sequence variants associated with blood pressure levels and heart disease, 10 of which could be are in or near genes encoding proteins and appear to be likely targets for drugs that are currently available or in development.
Largest study of its kind, supported by the NHLBI, finds multiple ethnicities impacted by the genetic variations.